JULIE FABREGAS-SCHINDLER: Open Payments
NPI 1013906452 · AUGUSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 54 payments from 13 companies in 2025. Trend: 2023 $718 · 2024 $328 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 33 | $207 |
| Astellas Pharma US Inc | 2 | $166 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $67 |
| GlaxoSmithKline, LLC. | 3 | $56 |
| Lilly USA, LLC | 3 | $53 |
| Abbott Laboratories | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $37 |
| Corcept Therapeutics | 1 | $21 |
| SHIELD THERAPEUTICS INC | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: Veozah, OTEZLA, REPATHA, Kerendia, SHINGRIX, VERQUVO, MOUNJARO, Korlym.
Industry payments across GA — which companies pay providers there.
